An increasing number of specialists and non-specialists are developing clinical programs to treat and cure hepatitis C virus (HCV). The goal of this paper is to evaluate and describe optimal strategies to improve outcomes related to HCV care delivery.

This study examins the use and pharmacotherapy of direct acting antivirals to treat hepatitis C in transplant patients receiving positive donor hearts. While results of this practice have proven successful, management of drug-drug interactions between transplant medications and DAAs is necessary to ensure safety and efficacy.

This multi-site study evaluated the effectiveness of a clinical pharmacist-driven HCV delivery model in an open system. With an overall sustained virologic response (SVR) rate of 95% (per protocol), the clinical pharmacist-driven HCV treatment model was found to be effective and comparable to other real-world studies with specialist, non-specialist, and non-hepatology providers.

In this ambispective cohort study of patients referred to an outpatient Infectious Diseases Clinic for chronic HCV, we found significant differences in patient demographics, drug interactions, and time to treat between HCV monoinfected and HIV/HCV coinfected patients. This study provides a broad, yet concise overview of the differences in caring for patients with and without HIV/HCV coinfection.

The objective of this study was to better define the association of hepatitis C-positive donors with heart transplant volumes, wait-list duration, and mortality at 1 year. Findings suggest that infection is well-tolerated and curable in heart transplant recipients with donor-derived hepatitis C, and 1-year survival is equivalent to that in recipients of hepatitis C-negative donors.

This study highlighted baseline factors associated with HCV treatment failure in 1,253 patients at four United States institutions. Most likely predictors of treatment failure in our dataset were older age, presence of hepatocellular carcinoma, and private versus public insurance, which appeared in 89%, 84%, and 80% of bootstrap models, respectively.

Rates of persistent viremia (PV), defined as a detectable hepatitis c (HCV) viral load after 4 weeks of direct-acting antiviral (DAA) therapy, were low (5.7%) in a real-world cohort of 983 patients. High sustained virologic response (SVR) rates were achieved both in patients with PV (92.9%) and those with rapid virologic response (RVR) (96.5%), without significant differences.

This case series describes the safety and effectiveness outcomes of patietns requiring HCV DAA tablet manipulation. This data along with a comprehensive review of other reports of DAA manipulation demonstrate the safety and efficacy of tablet manipulation.

This report discusses reasons anticancer therapies may need to be initiated on admission, challenges of doing so, perspectives and experiences from 3 unique HSSPs on addressing these challenges, and finally, best practice recommendations in managing high cost oral anticancer therapies for admitted patients.

The purpose of this article is to describe medication alternatives available for use in patients with certain bleeding disorders during the intranasal desmopressin recall. Intranasal desmopressin plays a key role in treatment of these patients and the recall is expected to impact availability until mid to late 2023. We hope the details of the article can help other institutions select the best treatment alternative for their patients during this time.